Mitchell P. Levesque, Ph.D. - Publications

2005 Duke University, Durham, NC 
Bioinformatics, Genetics

7/145 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2010 De Smet I, Lau S, Voss U, Vanneste S, Benjamins R, Rademacher EH, Schlereth A, De Rybel B, Vassileva V, Grunewald W, Naudts M, Levesque MP, Ehrismann JS, Inzé D, Luschnig C, et al. Bimodular auxin response controls organogenesis in Arabidopsis. Proceedings of the National Academy of Sciences of the United States of America. 107: 2705-10. PMID 20133796 DOI: 10.1073/Pnas.0915001107  1
2008 De Smet I, Vassileva V, De Rybel B, Levesque MP, Grunewald W, Van Damme D, Van Noorden G, Naudts M, Van Isterdael G, De Clercq R, Wang JY, Meuli N, Vanneste S, Friml J, Hilson P, et al. Receptor-like kinase ACR4 restricts formative cell divisions in the Arabidopsis root. Science (New York, N.Y.). 322: 594-7. PMID 18948541 DOI: 10.1126/Science.1160158  1
2007 Cui H, Levesque MP, Vernoux T, Jung JW, Paquette AJ, Gallagher KL, Wang JY, Blilou I, Scheres B, Benfey PN. An evolutionarily conserved mechanism delimiting SHR movement defines a single layer of endodermis in plants. Science (New York, N.Y.). 316: 421-5. PMID 17446396 DOI: 10.1126/Science.1139531  1
2006 Levesque MP, Vernoux T, Busch W, Cui H, Wang JY, Blilou I, Hassan H, Nakajima K, Matsumoto N, Lohmann JU, Scheres B, Benfey PN. Whole-genome analysis of the SHORT-ROOT developmental pathway in Arabidopsis. Plos Biology. 4: e143. PMID 16640459 DOI: 10.1371/Journal.Pbio.0040143  1
2005 Lee JY, Levesque M, Benfey PN. High-throughput RNA isolation technologies. New tools for high-resolution gene expression profiling in plant systems. Plant Physiology. 138: 585-90. PMID 15955922 DOI: 10.1104/Pp.105.061812  1
2004 Levesque MP, Benfey PN. Systems biology. Current Biology : Cb. 14: R179-80. PMID 15028228 DOI: 10.1016/j.cub.2004.02.012  1
2003 Levesque M, Shasha D, Kim W, Surette MG, Benfey PN. Trait-to-gene: a computational method for predicting the function of uncharacterized genes. Current Biology : Cb. 13: 129-33. PMID 12546786 DOI: 10.1016/S0960-9822(03)00009-5  1
Low-probability matches
2008 Swarup K, Benková E, Swarup R, Casimiro I, Péret B, Yang Y, Parry G, Nielsen E, De Smet I, Vanneste S, Levesque MP, Carrier D, James N, Calvo V, Ljung K, et al. The auxin influx carrier LAX3 promotes lateral root emergence. Nature Cell Biology. 10: 946-54. PMID 18622388 DOI: 10.1038/ncb1754  0.16
2021 Vergara IA, Mintoff CP, Sandhu S, McIntosh L, Young RJ, Wong SQ, Colebatch A, Cameron DL, Kwon JL, Wolfe R, Peng A, Ellul J, Dou X, Fedele C, Boyle S, ... ... Levesque MP, et al. Evolution of late-stage metastatic melanoma is dominated by aneuploidy and whole genome doubling. Nature Communications. 12: 1434. PMID 33664264 DOI: 10.1038/s41467-021-21576-8  0.04
2020 Lazar I, Fabre B, Feng Y, Khateb A, Turko P, Martinez-Gomez MJ, Frederick DT, Levesque MP, Feld L, Zhang G, Zhang T, James B, Shklover J, Avitan Hersh E, Livneh I, et al. SPANX control of Lamin A/C modulates nuclear architecture and promotes melanoma growth. Molecular Cancer Research : McR. PMID 32571981 DOI: 10.1158/1541-7786.Mcr-20-0291  0.04
2019 Tuncer E, Calçada RR, Zingg D, Varum S, Cheng P, Freiberger SN, Deng CX, Kleiter I, Levesque MP, Dummer R, Sommer L. SMAD signaling promotes melanoma metastasis independently of phenotype switching. The Journal of Clinical Investigation. 130. PMID 31039140 DOI: 10.1172/Jci94295  0.04
2017 Xue G, Kohler R, Tang F, Hynx D, Wang Y, Orso F, Prêtre V, Ritschard R, Hirschmann P, Cron P, Roloff T, Dummer R, Mandalà M, Bichet S, Genoud C, ... ... Levesque MP, et al. mTORC1/autophagy-regulated MerTK in mutant BRAFV600 melanoma with acquired resistance to BRAF inhibition. Oncotarget. PMID 28599271 DOI: 10.18632/oncotarget.18213  0.04
2017 Nosrati A, Tsai KK, Goldinger SM, Tumeh P, Grimes B, Loo K, Algazi AP, Nguyen-Kim TD, Levesque M, Dummer R, Hamid O, Daud A. Evaluation of clinicopathological factors in PD-1 response: derivation and validation of a prediction scale for response to PD-1 monotherapy. British Journal of Cancer. PMID 28324889 DOI: 10.1038/Bjc.2017.70  0.04
2017 Haueis SA, Kränzlin P, Mangana J, Cheng PF, Urosevic-Maiwald M, Braun RP, Levesque MP, Dummer R, Goldinger SM. Does the distribution pattern of brain metastases during BRAF inhibitor therapy reflect phenotype switching? Melanoma Research. PMID 28099366 DOI: 10.1097/Cmr.0000000000000338  0.04
2016 Huber R, Meier B, Otsuka A, Fenini G, Satoh T, Gehrke S, Widmer D, Levesque MP, Mangana J, Kerl K, Gebhardt C, Fujii H, Nakashima C, Nonomura Y, Kabashima K, et al. Tumour hypoxia promotes melanoma growth and metastasis via High Mobility Group Box-1 and M2-like macrophages. Scientific Reports. 6: 29914. PMID 27426915 DOI: 10.1038/Srep29914  0.04
2016 Claps G, Cheli Y, Zhang T, Scortegagna M, Lau E, Kim H, Qi J, Li JL, James B, Dzung A, Levesque MP, Dummer R, Hayward NK, Bosenberg M, Brown KM, et al. A Transcriptionally Inactive ATF2 Variant Drives Melanomagenesis. Cell Reports. PMID 27210757 DOI: 10.1016/J.Celrep.2016.04.072  0.04
2016 Smith MP, Brunton H, Rowling EJ, Ferguson J, Arozarena I, Miskolczi Z, Lee JL, Girotti MR, Marais R, Levesque MP, Dummer R, Frederick DT, Flaherty KT, Cooper ZA, Wargo JA, et al. Inhibiting Drivers of Non-mutational Drug Tolerance Is a Salvage Strategy for Targeted Melanoma Therapy. Cancer Cell. 29: 270-284. PMID 26977879 DOI: 10.1016/J.Ccell.2016.02.003  0.04
2016 Paulitschke V, Eichhoff O, Cheng PF, Levesque MP, Höller C. Proteomics approaches to understanding mitogen-activated protein kinase inhibitor resistance in melanoma. Current Opinion in Oncology. PMID 26742019 DOI: 10.1097/Cco.0000000000000261  0.04
2015 Rozati S, Cheng PF, Widmer DS, Fujii K, Levesque MP, Dummer R. Romidepsin and azacitidine synergize in their epigenetic modulatory effects to induce apoptosis in CTCL. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 26660520 DOI: 10.1158/1078-0432.Ccr-15-1435  0.04
2015 Del Prete V, Chaloupka K, Holzmann D, Fink D, Levesque M, Dummer R, Goldinger SM. Noncutaneous Melanomas: A Single-Center Analysis. Dermatology (Basel, Switzerland). PMID 26618350 DOI: 10.1159/000441444  0.04
2015 Levesque MP, Dummer R, Beerenwinkel N. Perturbing resistance: a network perspective. Pigment Cell & Melanoma Research. PMID 26471867 DOI: 10.1111/Pcmr.12431  0.04
2015 Widmer DS, Eichhoff OM, Dummer R, Levesque MP. Melanoma's next top model, it is in the air. Experimental Dermatology. 24: 659-60. PMID 25977109 DOI: 10.1111/Exd.12757  0.04
2015 Cheng PF, Shakhova O, Widmer DS, Eichhoff OM, Zingg D, Frommel SC, Belloni B, Raaijmakers MI, Goldinger SM, Santoro R, Hemmi S, Sommer L, Dummer R, Levesque MP. Methylation-dependent SOX9 expression mediates invasion in human melanoma cells and is a negative prognostic factor in advanced melanoma. Genome Biology. 16: 42. PMID 25885555 DOI: 10.1186/S13059-015-0594-4  0.04
2015 Otsuka A, Levesque MP, Dummer R, Kabashima K. Hedgehog signaling in basal cell carcinoma. Journal of Dermatological Science. 78: 95-100. PMID 25766766 DOI: 10.1016/J.Jdermsci.2015.02.007  0.04
2015 Raaijmakers MI, Widmer DS, Maudrich M, Koch T, Langer A, Flace A, Schnyder C, Dummer R, Levesque MP. A new live-cell biobank workflow efficiently recovers heterogeneous melanoma cells from native biopsies. Experimental Dermatology. 24: 377-80. PMID 25739758 DOI: 10.1111/Exd.12683  0.04
2015 Dummer R, Goldinger SM, Paulitschke V, Levesque MP. Curing advanced melanoma by 2025. Current Opinion in Oncology. 27: 125-7. PMID 25646843 DOI: 10.1097/Cco.0000000000000168  0.04
2015 Guenova E, Skabytska Y, Hoetzenecker W, Weindl G, Sauer K, Tham M, Kim KW, Park JH, Seo JH, Ignatova D, Cozzio A, Levesque MP, Volz T, Köberle M, Kaesler S, et al. IL-4 abrogates T(H)17 cell-mediated inflammation by selective silencing of IL-23 in antigen-presenting cells. Proceedings of the National Academy of Sciences of the United States of America. 112: 2163-8. PMID 25646481 DOI: 10.1073/Pnas.1416922112  0.04
2015 Otsuka A, Dreier J, Cheng PF, Nägeli M, Lehmann H, Felderer L, Frew IJ, Matsushita S, Levesque MP, Dummer R. Hedgehog pathway inhibitors promote adaptive immune responses in basal cell carcinoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 21: 1289-97. PMID 25593302 DOI: 10.1158/1078-0432.Ccr-14-2110  0.04
2014 Venturelli S, Sinnberg TW, Berger A, Noor S, Levesque MP, Böcker A, Niessner H, Lauer UM, Bitzer M, Garbe C, Busch C. Epigenetic impacts of ascorbate on human metastatic melanoma cells. Frontiers in Oncology. 4: 227. PMID 25202679 DOI: 10.3389/Fonc.2014.00227  0.04
2014 Dreier J, Cheng PF, Bogdan Alleman I, Gugger A, Hafner J, Tschopp A, Goldinger SM, Levesque MP, Dummer R. Basal cell carcinomas in a tertiary referral centre: a systematic analysis. The British Journal of Dermatology. 171: 1066-72. PMID 24974741 DOI: 10.1111/bjd.13217  0.04
2014 Dummer R, Goldinger SM, Widmer D, Dreier J, Levesque MP. To B-(RAF) or not to be. The Journal of Investigative Dermatology. 134: 1200-1. PMID 24732335 DOI: 10.1038/Jid.2014.62  0.04
2014 Guenova E, Hoetzenecker W, Rozati S, Levesque MP, Dummer R, Cozzio A. Novel therapies for cutaneous T-cell lymphoma: what does the future hold? Expert Opinion On Investigational Drugs. 23: 457-67. PMID 24397291 DOI: 10.1517/13543784.2014.876407  0.04
2013 Widmer DS, Hoek KS, Cheng PF, Eichhoff OM, Biedermann T, Raaijmakers MI, Hemmi S, Dummer R, Levesque MP. Hypoxia contributes to melanoma heterogeneity by triggering HIF1α-dependent phenotype switching. The Journal of Investigative Dermatology. 133: 2436-43. PMID 23474946 DOI: 10.1038/Jid.2013.115  0.04
2013 Levesque MP, Krauss J, Koehler C, Boden C, Harris MP. New tools for the identification of developmentally regulated enhancer regions in embryonic and adult zebrafish. Zebrafish. 10: 21-9. PMID 23461416 DOI: 10.1089/Zeb.2012.0775  0.04
2013 Nestorov P, Battke F, Levesque MP, Gerberding M. The maternal transcriptome of the crustacean Parhyale hawaiensis is inherited asymmetrically to invariant cell lineages of the ectoderm and mesoderm. Plos One. 8: e56049. PMID 23418507 DOI: 10.1371/Journal.Pone.0056049  0.04
2013 Raaijmakers MI, Rozati S, Goldinger SM, Widmer DS, Dummer R, Levesque MP. Melanoma immunotherapy: historical precedents, recent successes and future prospects. Immunotherapy. 5: 169-82. PMID 23413908 DOI: 10.2217/Imt.12.162  0.04
2013 Grønskov K, Dooley CM, Østergaard E, Kelsh RN, Hansen L, Levesque MP, Vilhelmsen K, MøllgÃ¥rd K, Stemple DL, Rosenberg T. Mutations in c10orf11, a melanocyte-differentiation gene, cause autosomal-recessive albinism. American Journal of Human Genetics. 92: 415-21. PMID 23395477 DOI: 10.1016/J.Ajhg.2013.01.006  0.04
2013 Mongera A, Singh AP, Levesque MP, Chen YY, Konstantinidis P, Nüsslein-Volhard C. Genetic lineage labeling in zebrafish uncovers novel neural crest contributions to the head, including gill pillar cells. Development (Cambridge, England). 140: 916-25. PMID 23362350 DOI: 10.1242/Dev.091066  0.04
2013 Das Thakur M, Salangsang F, Landman AS, Sellers WR, Pryer NK, Levesque MP, Dummer R, McMahon M, Stuart DD. Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance. Nature. 494: 251-5. PMID 23302800 DOI: 10.1038/Nature11814  0.04
2013 Rozati S, Naef L, Levesque MP, French LE, Dummer R. Real-life experience with pegylated interferon and conventional interferon in adjuvant melanoma therapy. Journal of Immunotherapy (Hagerstown, Md. : 1997). 36: 52-6. PMID 23211621 DOI: 10.1097/Cji.0B013E31827809C7  0.04
2012 Chen YY, Harris MP, Levesque MP, Nüsslein-Volhard C, Sonawane M. Heterogeneity across the dorso-ventral axis in zebrafish EVL is regulated by a novel module consisting of sox, snail1a and max genes. Mechanisms of Development. 129: 13-23. PMID 22522081 DOI: 10.1016/J.Mod.2012.03.003  0.04
2012 Mangana J, Levesque MP, Karpova MB, Dummer R. Sorafenib in melanoma. Expert Opinion On Investigational Drugs. 21: 557-68. PMID 22394203 DOI: 10.1517/13543784.2012.665872  0.04
2009 Reischauer S, Levesque MP, Nüsslein-Volhard C, Sonawane M. Lgl2 executes its function as a tumor suppressor by regulating ErbB signaling in the zebrafish epidermis. Plos Genetics. 5: e1000720. PMID 19911055 DOI: 10.1371/Journal.Pgen.1000720  0.04
2008 Dohmann EM, Levesque MP, Isono E, Schmid M, Schwechheimer C. Auxin responses in mutants of the Arabidopsis CONSTITUTIVE PHOTOMORPHOGENIC9 signalosome. Plant Physiology. 147: 1369-79. PMID 18467458 DOI: 10.1104/Pp.108.121061  0.04
2008 Dohmann EM, Levesque MP, De Veylder L, Reichardt I, Jürgens G, Schmid M, Schwechheimer C. The Arabidopsis COP9 signalosome is essential for G2 phase progression and genomic stability. Development (Cambridge, England). 135: 2013-22. PMID 18434413 DOI: 10.1242/Dev.020743  0.04
2021 Dzung A, Cheng P, Stoffel C, Tastanova A, Turko P, Levesque MP, Bosshard PP. Prolonged Unfrozen Storage and Repeated Freeze-Thawing of SARS-CoV-2 Patient Samples Have Minor Effects on SARS-CoV-2 Detectability by RT-PCR. The Journal of Molecular Diagnostics : Jmd. PMID 33775845 DOI: 10.1016/j.jmoldx.2021.03.003  0.01
2021 Kalaora S, Nagler A, Nejman D, Alon M, Barbolin C, Barnea E, Ketelaars SLC, Cheng K, Vervier K, Shental N, Bussi Y, Rotkopf R, Levy R, Benedek G, Trabish S, ... ... Levesque MP, et al. Identification of bacteria-derived HLA-bound peptides in melanoma. Nature. PMID 33731925 DOI: 10.1038/s41586-021-03368-8  0.01
2021 Irmisch A, Bonilla X, Chevrier S, Lehmann KV, Singer F, Toussaint NC, Esposito C, Mena J, Milani ES, Casanova R, Stekhoven DJ, Wegmann R, Jacob F, Sobottka B, Goetze S, ... ... Levesque MP, et al. The Tumor Profiler Study: integrated, multi-omic, functional tumor profiling for clinical decision support. Cancer Cell. PMID 33482122 DOI: 10.1016/j.ccell.2021.01.004  0.01
2021 Tusup M, Cheng PF, Picardi E, Raziunaite A, Dummer R, Levesque MP, French LE, Guenova E, Kundig TM, Pascolo S. Evaluation of the Interplay between the ADAR Editome and Immunotherapy in Melanoma. Non-Coding Rna. 7. PMID 33445472 DOI: 10.3390/ncrna7010005  0.01
2021 Ma M, Ghosh S, Tavernari D, Katarkar A, Clocchiatti A, Mazzeo L, Samarkina A, Epiney J, Yu YR, Ho PC, Levesque MP, Özdemir BC, Ciriello G, Dummer R, Dotto GP. Sustained androgen receptor signaling is a determinant of melanoma cell growth potential and tumorigenesis. The Journal of Experimental Medicine. 218. PMID 33112375 DOI: 10.1084/jem.20201137  0.01
2020 Hurkmans DP, Verdegaal EME, Hogan SA, de Wijn R, Hovestad L, van den Heuvel DMA, Ruijtenbeek R, Welters MJP, van Brakel M, Basak EA, Pinedo HM, Lamers CHJ, van de Werken HJG, Groten JP, Debets R, ... Levesque MP, et al. Blood-based kinase activity profiling: a potential predictor of response to immune checkpoint inhibition in metastatic cancer. Journal For Immunotherapy of Cancer. 8. PMID 33427690 DOI: 10.1136/jitc-2020-001607  0.01
2020 Turiello R, Capone M, Giannarelli D, Morretta E, Monti MC, Madonna G, Mallardo D, Festino L, Azzaro R, Levesque MP, Imhof L, Weide B, Amaral T, Chevrier M, Sucker A, et al. Serum CD73 is a prognostic factor in patients with metastatic melanoma and is associated with response to anti-PD-1 therapy. Journal For Immunotherapy of Cancer. 8. PMID 33361405 DOI: 10.1136/jitc-2020-001689  0.01
2020 Cerezo-Wallis D, Contreras-Alcalde M, Troulé K, Catena X, Mucientes C, Calvo TG, Cañón E, Tejedo C, Pennacchi PC, Hogan S, Kölblinger P, Tejero H, Chen AX, Ibarz N, Graña-Castro O, ... ... Levesque MP, et al. Midkine rewires the melanoma microenvironment toward a tolerogenic and immune-resistant state. Nature Medicine. PMID 33077955 DOI: 10.1038/s41591-020-1073-3  0.01
2020 Newell F, Wilmott JS, Johansson PA, Nones K, Addala V, Mukhopadhyay P, Broit N, Amato CM, Van Gulick R, Kazakoff SH, Patch AM, Koufariotis LT, Lakis V, Leonard C, Wood S, ... ... Levesque MP, et al. Whole-genome sequencing of acral melanoma reveals genomic complexity and diversity. Nature Communications. 11: 5259. PMID 33067454 DOI: 10.1038/s41467-020-18988-3  0.01
2020 Bauer M, Nascakova Z, Mihai AI, Cheng PF, Levesque MP, Lampart S, Hurwitz R, Pfannkuch L, Dobrovolna J, Jacobs M, Bartfeld S, Dohlman A, Shen X, Gall AA, Salama NR, et al. The ALPK1/TIFA/NF-κB axis links a bacterial carcinogen to R-loop-induced replication stress. Nature Communications. 11: 5117. PMID 33037203 DOI: 10.1038/s41467-020-18857-z  0.01
2020 Burla J, Bluemel S, Biedermann L, Barysch MJ, Dummer R, Levesque MP, Gubler C, Morell B, Rogler G, Scharl M. Retrospective Analysis of Treatment and Complications of Immune Checkpoint Inhibitor-Associated Colitis: Histological Ulcerations as Potential Predictor for a Steroid-Refractory Disease Course. Inflammatory Intestinal Diseases. 5: 109-116. PMID 32999883 DOI: 10.1159/000507579  0.01
2020 Banik I, Cheng PF, Dooley CM, Travnickova J, Merteroglu M, Dummer R, Patton EE, Busch-Nentwich EM, Levesque MP. NRAS melanoma tumor formation is reduced by p38-MAPK14 activation in zebrafish models and NRAS-mutated human melanoma cells. Pigment Cell & Melanoma Research. PMID 32910840 DOI: 10.1111/Pcmr.12925  0.01
2020 Teh JL, Erkes DA, Cheng PF, Tiago M, Wilski NA, Field CO, Chervoneva I, Levesque MP, Xu X, Dummer R, Aplin AE. Activation of CD8+ T cells contributes to anti-tumor effects of CDK4/6 inhibitors plus MEK inhibitors. Cancer Immunology Research. PMID 32661093 DOI: 10.1158/2326-6066.Cir-19-0743  0.01
2020 Ziegler JS, Kroeze S, Hilbers ML, Imhof L, Guckenberger M, Levesque MP, Dummer R, Cheng P, Mangana J. Toxicity of combined targeted therapy and concurrent radiotherapy in metastatic melanoma patients: a single-center retrospective analysis. Melanoma Research. PMID 32658050 DOI: 10.1097/Cmr.0000000000000682  0.01
2020 Vandamme N, Denecker G, Bruneel K, Blancke G, Akay Ö, Taminau J, De Coninck J, De Smedt E, Skrypek N, Van Loocke W, Wouters J, Nittner D, Köhler C, Darling DS, Cheng PF, ... ... Levesque MP, et al. The EMT transcription factor ZEB2 promotes proliferation of primary and metastatic melanoma while suppressing an invasive, mesenchymal-like phenotype. Cancer Research. PMID 32503808 DOI: 10.1158/0008-5472.Can-19-2373  0.01
2020 Nguyen MQ, Teh JLF, Purwin TJ, Chervoneva I, Davies MA, Nathanson KL, Cheng PF, Levesque MP, Dummer R, Aplin AE. Targeting PHGDH upregulation reduces glutathione levels and re-sensitizes resistant NRAS mutant melanoma to MEK inhibition. The Journal of Investigative Dermatology. PMID 32389536 DOI: 10.1016/J.Jid.2020.02.047  0.01
2020 Kaufmann C, Kempf W, Mangana J, Cheng P, Emberger M, Lang R, Kaiser AK, Lattmann E, Levesque M, Dummer R, Koelblinger P. The role of Cyclin D1 and Ki-67 in the development and prognostication of thin melanoma. Histopathology. PMID 32374893 DOI: 10.1111/His.14139  0.01
2020 Basler L, Gabryś HS, Hogan SA, Pavic M, Bogowicz M, Vuong D, Tanadini-Lang S, Foerster R, Kudura K, Huellner MW, Dummer R, Guckenberger M, Levesque MP. Radiomics, tumor volume and blood biomarkers for early prediction of pseudoprogression in metastatic melanoma patients treated with immune checkpoint inhibition. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 32253232 DOI: 10.1158/1078-0432.Ccr-20-0020  0.01
2020 Uka R, Britschgi C, Krättli A, Matter C, Mihic D, Okoniewski MJ, Gualandi M, Stupp R, Cinelli P, Dummer R, Levesque MP, Shakhova O. Temporal activation of WNT/β-catenin signaling is sufficient to inhibit SOX10 expression and block melanoma growth. Oncogene. PMID 32238882 DOI: 10.1038/S41388-020-1267-7  0.01
2020 Cheng P, Levesque MP, Dummer R, Mangana J. Targeting complex, adaptive responses in melanoma therapy. Cancer Treatment Reviews. 86: 101997. PMID 32179238 DOI: 10.1016/J.Ctrv.2020.101997  0.01
2020 McLuckie M, Robotti F, Sanchez-Macedo N, Enderlin D, Frese L, Cheng PF, Levesque MP, Egaña JT, Poulikakos D, Ferrari A, Lindenblatt N. Lipoconstruct surface topography grating size influences vascularization onset in the dorsal skinfold chamber model. Acta Biomaterialia. PMID 32044460 DOI: 10.1016/J.Actbio.2020.01.050  0.01
2019 Wenzina J, Holzner S, Puujalka E, Cheng PF, Forsthuber A, Neumüller K, Schossleitner K, Lichtenberger BM, Levesque MP, Petzelbauer P. Inhibition of p38/MK2 signaling prevents vascular invasion of melanoma. The Journal of Investigative Dermatology. PMID 31622599 DOI: 10.1016/J.Jid.2019.08.451  0.01
2019 Nagler A, Vredevoogd DW, Alon M, Cheng PF, Trabish S, Kalaora S, Arafeh R, Goldin V, Levesque MP, Peeper DS, Samuels Y. A genome-wide CRISPR screen identifies FBXO42 involvement in resistance towards MEK inhibition in NRAS mutant melanoma. Pigment Cell & Melanoma Research. PMID 31549767 DOI: 10.1111/Pcmr.12825  0.01
2019 Freiberger SN, Morand GB, Turko P, Wager U, Dummer R, Hüllner M, Holzmann D, Rupp NJ, Levesque MP. Morpho-Molecular Assessment Indicates New Prognostic Aspects and Personalized Therapeutic Options in Sinonasal Melanoma. Cancers. 11. PMID 31500314 DOI: 10.3390/Cancers11091329  0.01
2019 Aloia A, Müllhaupt D, Chabbert CD, Eberhart T, Flueckiger S, Vukolic A, Eichhoff OM, Irmisch A, Alexander LT, Scibona E, Frederick DT, Miao B, Tian T, Cheng C, Kwong LN, ... ... Levesque MP, et al. A fatty acid oxidation-dependent metabolic shift regulates the adaptation of -mutated melanoma to MAPK inhibitors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31375515 DOI: 10.1158/1078-0432.Ccr-19-0253  0.01
2019 Newell F, Kong Y, Wilmott JS, Johansson PA, Ferguson PM, Cui C, Li Z, Kazakoff SH, Burke H, Dodds TJ, Patch AM, Nones K, Tembe V, Shang P, van der Weyden L, ... ... Levesque MP, et al. Whole-genome landscape of mucosal melanoma reveals diverse drivers and therapeutic targets. Nature Communications. 10: 3163. PMID 31320640 DOI: 10.1038/S41467-019-11107-X  0.01
2019 Paulitschke V, Eichhoff O, Gerner C, Paulitschke P, Bileck A, Mohr T, Cheng PF, Leitner A, Guenova E, Saulite I, Freiberger SN, Irmisch A, Knapp B, Zila N, Chatziisaak TP, ... ... Levesque MP, et al. Proteomic identification of a marker signature for MAPKi resistance in melanoma. The Embo Journal. e95874. PMID 31267558 DOI: 10.15252/Embj.201695874  0.01
2019 Varum S, Baggiolini A, Zurkirchen L, Atak ZK, Cantù C, Marzorati E, Bossart R, Wouters J, Häusel J, Tuncer E, Zingg D, Veen D, John N, Balz M, Levesque MP, et al. Yin Yang 1 Orchestrates a Metabolic Program Required for Both Neural Crest Development and Melanoma Formation. Cell Stem Cell. 24: 637-653.e9. PMID 30951662 DOI: 10.1016/J.Stem.2019.03.011  0.01
2019 Li Y, Tinoco R, Elmén L, Segota I, Xian Y, Fujita Y, Sahu A, Zarecki R, Marie K, Feng Y, Khateb A, Frederick DT, Ashkenazi SK, Kim H, Perez EG, ... ... Levesque MP, et al. Gut microbiota dependent anti-tumor immunity restricts melanoma growth in Rnf5 mice. Nature Communications. 10: 1492. PMID 30940817 DOI: 10.1038/S41467-019-09525-Y  0.01
2019 Fässler M, Diem S, Mangana J, Hasan Ali O, Berner F, Bomze D, Ring S, Niederer R, Del Carmen Gil Cruz C, Pérez Shibayama CI, Krolik M, Siano M, Joerger M, Recher M, Risch L, ... ... Levesque MP, et al. Antibodies as biomarker candidates for response and survival to checkpoint inhibitors in melanoma patients. Journal For Immunotherapy of Cancer. 7: 50. PMID 30786924 DOI: 10.1186/S40425-019-0523-2  0.01
2019 Poźniak J, Nsengimana J, Laye JP, O'Shea SJ, Diaz JMS, Droop AP, Filia A, Harland M, Davies JR, Mell T, Randerson-Moor JA, Muralidhar S, Hogan SA, Freiberger SN, Levesque MP, et al. Genetic and Environmental Determinants of Immune Response to Cutaneous Melanoma. Cancer Research. PMID 30773503 DOI: 10.1158/0008-5472.Can-18-2864  0.01
2019 Diem S, Fässler M, Bomze D, Ali OH, Berner F, Niederer R, Hillmann D, Mangana J, Levesque MP, Dummer R, Risch L, Recher M, Risch M, Flatz L. Immunoglobulin G and Subclasses as Potential Biomarkers in Metastatic Melanoma Patients Starting Checkpoint Inhibitor Treatment. Journal of Immunotherapy (Hagerstown, Md. : 1997). PMID 30768543 DOI: 10.1097/Cji.0000000000000255  0.01
2019 Sand J, Fenini G, Grossi S, Hennig P, Di Filippo M, Levesque M, Werner S, French LE, Beer HD. The NLRP1 Inflammasome Pathway Is Silenced in Cutaneous Squamous Cell Carcinoma. The Journal of Investigative Dermatology. 139: 1788-1797.e6. PMID 30738816 DOI: 10.1016/J.Jid.2019.01.025  0.01
2019 Cheng P, Freiberger S, Panetti C, Irmisch A, Dummer R, Levesque M. Integrative RNAseq and target panel sequencing reveals common and distinct innate and adaptive resistance mechanisms to BRAF inhibitors Annals of Oncology. 30: v547. DOI: 10.1093/Annonc/Mdz255.028  0.01
2018 Hogan SA, Courtier A, Cheng PF, Jaberg-Bentele NF, Goldinger SM, Manuel M, Perez S, Plantier N, Mouret JF, Nguyen-Kim TDL, Raaijmakers MM, Kvistborg P, Pasqual N, Haanen JBAG, Dummer R, ... Levesque MP, et al. Peripheral blood TCR repertoire profiling may facilitate patient stratification for immunotherapy against melanoma. Cancer Immunology Research. PMID 30425105 DOI: 10.1158/2326-6066.Cir-18-0136  0.01
2018 Singer F, Irmisch A, Toussaint NC, Grob L, Singer J, Thurnherr T, Beerenwinkel N, Levesque MP, Dummer R, Quagliata L, Rothschild SI, Wicki A, Beisel C, Stekhoven DJ. SwissMTB: establishing comprehensive molecular cancer diagnostics in Swiss clinics. Bmc Medical Informatics and Decision Making. 18: 89. PMID 30373609 DOI: 10.1186/S12911-018-0680-0  0.01
2018 Koelblinger P, Emberger M, Drach M, Cheng PF, Lang R, Levesque MP, Bauer JW, Dummer R. Increased tumour cell PD-L1-expression, macrophage and dendritic cell infiltration characterise the tumour microenvironment of ulcerated primary melanomas. Journal of the European Academy of Dermatology and Venereology : Jeadv. PMID 30357969 DOI: 10.1111/jdv.15302  0.01
2018 Pich C, Meylan P, Mastelic-Gavillet B, Nguyen NT, Loyon R, Trang BK, Moser H, Moret C, Goepfert C, Hafner J, Levesque MP, Romero P, Jandus C, Michalik L. Induction of paracrine signaling in metastatic melanoma cells by PPARγ agonist rosiglitazone activates stromal cells and enhances tumor growth. Cancer Research. PMID 30185551 DOI: 10.1158/0008-5472.Can-18-0912  0.01
2018 Ma Q, Dieterich LC, Ikenberg K, Bachmann SB, Mangana J, Proulx ST, Amann VC, Levesque MP, Dummer R, Baluk P, McDonald DM, Detmar M. Unexpected contribution of lymphatic vessels to promotion of distant metastatic tumor spread. Science Advances. 4: eaat4758. PMID 30101193 DOI: 10.1126/Sciadv.Aat4758  0.01
2018 Zingg D, Debbache J, Peña-Hernández R, Antunes AT, Schaefer SM, Cheng PF, Zimmerli D, Haeusel J, Calçada RR, Tuncer E, Zhang Y, Bossart R, Wong KK, Basler K, Dummer R, ... ... Levesque MP, et al. EZH2-Mediated Primary Cilium Deconstruction Drives Metastatic Melanoma Formation. Cancer Cell. 34: 69-84.e14. PMID 30008323 DOI: 10.1016/J.Ccell.2018.06.001  0.01
2018 Krieg C, Nowicka M, Guglietta S, Schindler S, Hartmann FJ, Weber LM, Dummer R, Robinson MD, Levesque MP, Becher B. Author Correction: High-dimensional single-cell analysis predicts response to anti-PD-1 immunotherapy. Nature Medicine. PMID 29967347 DOI: 10.1038/S41591-018-0094-7  0.01
2018 Hogan SA, Levesque MP, Cheng PF. Melanoma Immunotherapy: Next-Generation Biomarkers. Frontiers in Oncology. 8: 178. PMID 29896449 DOI: 10.3389/Fonc.2018.00178  0.01
2018 García-Martín AB, Zwicky P, Gruber T, Matti C, Moalli F, Stein JV, Francisco D, Enzmann G, Levesque MP, Hewer E, Lyck R. VLA-4 mediated adhesion of melanoma cells on the blood-brain barrier is the critical cue for melanoma cell intercalation and barrier disruption. Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism. 271678X18775887. PMID 29762071 DOI: 10.1177/0271678X18775887  0.01
2018 Sinnberg T, Niessner H, Levesque MP, Dettweiler C, Garbe C, Busch C. Embryonic bone morphogenetic protein and nodal induce invasion in melanocytes and melanoma cells. Biology Open. 7. PMID 29716947 DOI: 10.1242/Bio.032656  0.01
2018 Brüggen MC, Mangana J, Irmisch A, French LE, Levesque MP, Cheng PF, Dummer R. Methadone - not a magic bullet in melanoma therapy. Experimental Dermatology. PMID 29577418 DOI: 10.1111/Exd.13543  0.01
2018 Zila N, Bileck A, Muqaku B, Janker L, Eichhoff OM, Cheng PF, Dummer R, Levesque MP, Gerner C, Paulitschke V. Proteomics-based insights into mitogen-activated protein kinase inhibitor resistance of cerebral melanoma metastases. Clinical Proteomics. 15: 13. PMID 29541007 DOI: 10.1186/S12014-018-9189-X  0.01
2018 Sinnberg T, Levesque MP, Krochmann J, Cheng PF, Ikenberg K, Meraz-Torres F, Niessner H, Garbe C, Busch C. Wnt-signaling enhances neural crest migration of melanoma cells and induces an invasive phenotype. Molecular Cancer. 17: 59. PMID 29454361 DOI: 10.1186/S12943-018-0773-5  0.01
2018 Restivo G, Diener J, Cheng PF, Kiowski G, Bonalli M, Biedermann T, Reichmann E, Levesque MP, Dummer R, Sommer L. Publisher Correction: The low affinity neurotrophin receptor CD271 regulates phenotype switching in melanoma. Nature Communications. 9: 314. PMID 29358574 DOI: 10.1038/S41467-018-02850-8  0.01
2018 Krieg C, Nowicka M, Guglietta S, Schindler S, Hartmann FJ, Weber LM, Dummer R, Robinson MD, Levesque MP, Becher B. High-dimensional single-cell analysis predicts response to anti-PD-1 immunotherapy. Nature Medicine. PMID 29309059 DOI: 10.1038/Nm.4466  0.01
2018 Koelblinger P, Levesque MP, Kaufmann C, Sülberg H, Hinke A, Hoffmann M, Brunner G, Dummer R. A prognostic gene-signature based identification of high-risk thin melanomas. Journal of Clinical Oncology. 36: e21575-e21575. DOI: 10.1200/Jco.2018.36.15_Suppl.E21575  0.01
2017 Silina K, Soltermann A, Movahedian Attar F, Casanova R, Uckeley ZM, Thut H, Wandres M, Isajevs S, Cheng PF, Curioni Fontecedro A, Foukas P, Levesque MP, Moch H, Linē A, van den Broek M. Germinal centers determine the prognostic relevance of tertiary lymphoid structures and are impaired by corticosteroids in lung squamous cell carcinoma. Cancer Research. PMID 29279354 DOI: 10.1158/0008-5472.Can-17-1987  0.01
2017 Singer J, Irmisch A, Ruscheweyh HJ, Singer F, Toussaint NC, Levesque MP, Stekhoven DJ, Beerenwinkel N. Bioinformatics for precision oncology. Briefings in Bioinformatics. PMID 29272324 DOI: 10.1093/Bib/Bbx143  0.01
2017 Restivo G, Diener J, Cheng PF, Kiowski G, Bonalli M, Biedermann T, Reichmann E, Levesque MP, Dummer R, Sommer L. low neurotrophin receptor CD271 regulates phenotype switching in melanoma. Nature Communications. 8: 1988. PMID 29215016 DOI: 10.1038/S41467-017-01573-6  0.01
2017 Qu Y, Olsen JR, Yuan X, Cheng PF, Levesque MP, Brokstad KA, Hoffman PS, Oyan AM, Zhang W, Kalland KH, Ke X. Small molecule promotes β-catenin citrullination and inhibits Wnt signaling in cancer. Nature Chemical Biology. PMID 29083417 DOI: 10.1038/Nchembio.2510  0.01
2017 Xue G, Kohler R, Tang F, Hynx D, Wang Y, Orso F, Prêtre V, Ritschard R, Hirschmann P, Cron P, Roloff T, Dummer R, Mandalà M, Bichet S, Genoud C, ... ... Levesque MP, et al. mTORC1/autophagy-regulated MerTK in mutant BRAFV600 melanoma with acquired resistance to BRAF inhibition. Oncotarget. 8: 69204-69218. PMID 29050198 DOI: 10.18632/Oncotarget.18213  0.01
2017 Singer J, Ruscheweyh HJ, Hofmann AL, Thurnherr T, Singer F, Toussaint NC, Ng CKY, Piscuoglio S, Beisel C, Christofori G, Dummer R, Hall MN, Krek W, Levesque M, Manz MG, et al. NGS-pipe: a flexible, easily extendable, and highly configurable framework for NGS analysis. Bioinformatics (Oxford, England). PMID 28968639 DOI: 10.1093/Bioinformatics/Btx540  0.01
2017 Neu J, Dziunycz PJ, Dzung A, Lefort K, Falke M, Denzler R, Freiberger SN, Iotzova-Weiss G, Kuzmanov A, Levesque MP, Dotto GP, Hofbauer GFL. miR-181a decelerates proliferation in cutaneous squamous cell carcinoma by targeting the proto-oncogene KRAS. Plos One. 12: e0185028. PMID 28931048 DOI: 10.1371/Journal.Pone.0185028  0.01
2017 Dummer R, Ramelyte E, Schindler S, Thürigen O, Levesque MP, Koelblinger P. MEK inhibition and immune responses in advanced melanoma. Oncoimmunology. 6: e1335843. PMID 28919996 DOI: 10.1080/2162402X.2017.1335843  0.01
2017 Ishida Y, Otsuka A, Tanaka H, Levesque MP, Dummer R, Kabashima K. HLA-A*26 is correlated with response to nivolumab in Japanese melanoma patients. The Journal of Investigative Dermatology. PMID 28736235 DOI: 10.1016/J.Jid.2017.06.023  0.01
2017 Viswanathan VS, Ryan MJ, Dhruv HD, Gill S, Eichhoff OM, Seashore-Ludlow B, Kaffenberger SD, Eaton JK, Shimada K, Aguirre AJ, Viswanathan SR, Chattopadhyay S, Tamayo P, Yang WS, Rees MG, ... ... Levesque MP, et al. Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway. Nature. PMID 28678785 DOI: 10.1038/Nature23007  0.01
2017 Nowicka M, Krieg C, Weber LM, Hartmann FJ, Guglietta S, Becher B, Levesque MP, Robinson MD. CyTOF workflow: differential discovery in high-throughput high-dimensional cytometry datasets. F1000research. 6: 748. PMID 28663787 DOI: 10.12688/F1000Research.11622.3  0.01
2017 Smith MP, Rowling EJ, Miskolczi Z, Ferguson J, Spoerri L, Haass NK, Sloss O, McEntegart S, Arozarena I, von Kriegsheim A, Rodriguez J, Brunton H, Kmarashev J, Levesque MP, Dummer R, et al. Targeting endothelin receptor signalling overcomes heterogeneity driven therapy failure. Embo Molecular Medicine. PMID 28606996 DOI: 10.15252/Emmm.201607156  0.01
2017 Mangana J, Cheng PF, Kaufmann C, Amann VC, Frauchiger AL, Stögner V, Held U, von Moos R, Michielin O, Braun RP, Levesque MP, Goldinger SM, Dummer R. Multicenter, real-life experience with checkpoint inhibitors and targeted therapy agents in advanced melanoma patients in Switzerland. Melanoma Research. PMID 28509765 DOI: 10.1097/Cmr.0000000000000359  0.01
2017 Levesque MP, Cheng PF, Raaijmakers MI, Saltari A, Dummer R. Metastatic melanoma moves on: translational science in the era of personalized medicine. Cancer Metastasis Reviews. PMID 28321632 DOI: 10.1007/S10555-017-9658-0  0.01
2017 Amaral T, Sinnberg T, Meier F, Krepler C, Levesque M, Niessner H, Garbe C. The mitogen-activated protein kinase pathway in melanoma part I - Activation and primary resistance mechanisms to BRAF inhibition. European Journal of Cancer (Oxford, England : 1990). PMID 28169047 DOI: 10.1016/J.Ejca.2016.12.010  0.01
2017 Amaral T, Sinnberg T, Meier F, Krepler C, Levesque M, Niessner H, Garbe C. MAPK pathway in melanoma part II-secondary and adaptive resistance mechanisms to BRAF inhibition. European Journal of Cancer (Oxford, England : 1990). PMID 28162869 DOI: 10.1016/J.Ejca.2016.12.012  0.01
2017 Antsiferova M, Piwko-Czuchra A, Cangkrama M, Wietecha M, Sahin D, Birkner K, Amann VC, Levesque M, Hohl D, Dummer R, Werner S. Activin promotes skin carcinogenesis by attraction and reprogramming of macrophages. Embo Molecular Medicine. 9: 27-45. PMID 27932444 DOI: 10.15252/Emmm.201606493  0.01
2016 Farsam V, Basu A, Gatzka M, Treiber N, Schneider LA, Mulaw MA, Lucas T, Kochanek S, Dummer R, Levesque MP, Wlaschek M, Scharffetter-Kochanek K. Senescent fibroblast-derived Chemerin promotes squamous cell carcinoma migration. Oncotarget. PMID 27907906 DOI: 10.18632/Oncotarget.13446  0.01
2016 Raaijmakers MI, Widmer DS, Narechania A, Eichhoff O, Freiberger SN, Wenzina J, Cheng PF, Mihic-Probst D, Desalle R, Dummer R, Levesque MP. Co-existence of BRAF and NRAS driver mutations in the same melanoma cells results in heterogeneity of targeted therapy resistance. Oncotarget. PMID 27791198 DOI: 10.18632/Oncotarget.12848  0.01
2016 Czyż M, Toma M, Gajos-Michniewicz A, Majchrzak K, Hoser G, Szemraj J, Nieborowska-Skorska M, Cheng P, Gritsyuk D, Levesque M, Dummer R, Sliwinski T, Skorski T. PARP1 inhibitor olaparib (Lynparza) exerts synthetic lethal effect against ligase 4-deficient melanomas. Oncotarget. PMID 27705909 DOI: 10.18632/Oncotarget.12270  0.01
2016 Thurneysen S, Cheng PF, Nagel HW, Kunz M, Jaberg-Bentele N, Nägeli M, Ziegler M, Guenova E, Goldinger SM, Mangana J, Levesque MP, Dummer R. An exploratory study investigating the metabolic activity and local cytokine profile in melanoma patients treated with pazopanib and paclitaxel. The British Journal of Dermatology. PMID 27168024 DOI: 10.1111/bjd.14727  0.01
2016 Goldinger SM, Tsai KK, Tumeh P, Hamid O, Nosrati A, Loo K, Grimes B, Algazi AP, Levesque MP, Dummer R, Daud A. Correlation between metastatic site and response to anti-Programmed Death-1 (PD-1) agents in melanoma. Journal of Clinical Oncology. 34: 9549-9549. DOI: 10.1200/Jco.2016.34.15_Suppl.9549  0.01
2016 Nosrati A, Goldinger SM, Tsai KK, Loo K, Tumeh P, Hamid O, Algazi AP, Levesque MP, Dummer R, Daud A. Derivation and validation of a prediction scale for response to PD-1 monotherapy. Journal of Clinical Oncology. 34: 9514-9514. DOI: 10.1200/Jco.2016.34.15_Suppl.9514  0.01
2015 Rolfs F, Huber M, Kuehne A, Kramer S, Haertel E, Muzumdar S, Wagner J, Tanner Y, Böhm F, Smola S, Zamboni N, Levesque MP, Dummer R, Beer HD, Hohl D, et al. Nrf2 Activation Promotes Keratinocyte Survival during Early Skin Carcinogenesis via Metabolic Alterations. Cancer Research. PMID 26530903 DOI: 10.1158/0008-5472.Can-15-0614  0.01
2015 Cheng PF, Dummer R, Levesque MP. Data mining The Cancer Genome Atlas in the era of precision cancer medicine. Swiss Medical Weekly. 145: w14183. PMID 26375999 DOI: 10.4414/Smw.2015.14183  0.01
2015 Krengel S, Widmer DS, Kerl K, Levesque MP, Schiestl C, Weibel L. Naevus spilus-type congenital melanocytic naevus associated with a novel NRAS codon 61 mutation. The British Journal of Dermatology. PMID 26302237 DOI: 10.1111/bjd.14105  0.01
2015 Gao X, Metzger U, Panza P, Mahalwar P, Alsheimer S, Geiger H, Maischein HM, Levesque MP, Templin M, Söllner C. A Floor-Plate Extracellular Protein-Protein Interaction Screen Identifies Draxin as a Secreted Netrin-1 Antagonist. Cell Reports. PMID 26190107 DOI: 10.1016/J.Celrep.2015.06.047  0.01
2015 Freiberger SN, Cheng PF, Iotzova-Weiss G, Neu J, Liu Q, Dziunycz P, Zibert JR, Dummer R, Skak K, Levesque MP, Hofbauer GF. Ingenol Mebutate Signals via PKC/MEK/ERK in Keratinocytes and Induces Interleukin Decoy Receptors IL1R2 and IL13RA2. Molecular Cancer Therapeutics. 14: 2132-42. PMID 26116359 DOI: 10.1158/1535-7163.Mct-15-0023-T  0.01
2015 Kim H, Frederick DT, Levesque MP, Cooper ZA, Feng Y, Krepler C, Brill L, Samuels Y, Hayward NK, Perlina A, Piris A, Zhang T, Halaban R, Herlyn MM, Brown KM, et al. Downregulation of the Ubiquitin Ligase RNF125 Underlies Resistance of Melanoma Cells to BRAF Inhibitors via JAK1 Deregulation. Cell Reports. 11: 1458-73. PMID 26027934 DOI: 10.1016/J.Celrep.2015.04.049  0.01
2015 Shakhova O, Cheng P, Mishra PJ, Zingg D, Schaefer SM, Debbache J, Häusel J, Matter C, Guo T, Davis S, Meltzer P, Mihic-Probst D, Moch H, Wegner M, Merlino G, Levesque MP, et al. Antagonistic cross-regulation between Sox9 and Sox10 controls an anti-tumorigenic program in melanoma. Plos Genetics. 11: e1004877. PMID 25629959 DOI: 10.1371/Journal.Pgen.1004877  0.01
2015 Zingg D, Debbache J, Schaefer SM, Tuncer E, Frommel SC, Cheng P, Arenas-Ramirez N, Haeusel J, Zhang Y, Bonalli M, McCabe MT, Creasy CL, Levesque MP, Boyman O, Santoro R, et al. The epigenetic modifier EZH2 controls melanoma growth and metastasis through silencing of distinct tumour suppressors. Nature Communications. 6: 6051. PMID 25609585 DOI: 10.1038/Ncomms7051  0.01
2015 Goldinger SM, Mangana J, Frauchiger AL, Kaufmann C, Held U, Von Moos R, Romano E, Michielin O, Levesque MP, Dummer R. Real life experience with check point and kinase inhibitors in Swiss advanced melanoma patients. Journal of Clinical Oncology. 33: e20064-e20064. DOI: 10.1200/Jco.2015.33.15_Suppl.E20064  0.01
2014 Barysch MJ, Levesque MP, Cheng P, Karpova MB, Mihic-Probst D, Civenni G, Shakhova O, Sommer L, Biedermann T, Schiestl C, Dummer R. Coexpression of SOX10/CD271 (p75(NTR)) and β-Galactosidase in Large to Giant Congenital Melanocytic Nevi of Pediatric Patients. Dermatopathology (Basel, Switzerland). 1: 35-46. PMID 27047921 DOI: 10.1159/000362490  0.01
2012 Baumbach J, Levesque MP, Raff JW. Centrosome loss or amplification does not dramatically perturb global gene expression in Drosophila. Biology Open. 1: 983-93. PMID 23213376 DOI: 10.1242/Bio.20122238  0.01
2020 Rabbie R, Ansari-Pour N, Cast O, Lau D, Scott F, Welsh SJ, Parkinson C, Khoja L, Moore L, Tullett M, Wong K, Ferreira I, Gómez JMM, Levesque M, Gallagher FA, et al. Multi-site clonality analysis uncovers pervasive heterogeneity across melanoma metastases. Nature Communications. 11: 4306. PMID 32855398 DOI: 10.1038/S41467-020-18060-0  0
2019 Basler L, Gabrys H, Hogan SA, Bogowicz M, Vuong D, Huellner M, Tanadini-Lang S, Foerster R, Dummer R, Guckenberger M, Levesque MP. Delta-radiomics for prediction of pseudoprogression in malignant melanoma treated with immune checkpoint inhibition. Journal of Clinical Oncology. 37: 9575-9575. DOI: 10.1200/Jco.2019.37.15_Suppl.9575  0
2018 Clocchiatti A, Ghosh S, Procopio MG, Mazzeo L, Bordignon P, Ostano P, Goruppi S, Bottoni G, Katarkar A, Levesque M, Kölblinger P, Dummer R, Neel V, Özdemir BC, Dotto GP. Androgen receptor functions as transcriptional repressor of cancer-associated fibroblast activation. The Journal of Clinical Investigation. PMID 30395538 DOI: 10.1172/Jci99159  0
2018 Rambow F, Rogiers A, Marin-Bejar O, Aibar S, Femel J, Dewaele M, Karras P, Brown D, Chang YH, Debiec-Rychter M, Adriaens C, Radaelli E, Wolter P, Bechter O, Dummer R, ... Levesque M, et al. Toward Minimal Residual Disease-Directed Therapy in Melanoma. Cell. PMID 30017245 DOI: 10.1016/J.Cell.2018.06.025  0
2018 Hurkmans D, Verdegaal EME, Schindler SA, Basak EA, Heuvel DMAvd, Wijn Rd, Ruijtenbeek R, Groten JP, Dummer R, Koolen SLW, Welters MJP, Mathijssen RHJ, Kapiteijn E, Aerts JGJV, Levesque MP, et al. Blood-based multiplex kinase activity profiling as a predictive marker for clinical response to checkpoint blockade in advanced melanoma. Journal of Clinical Oncology. 36: 9579-9579. DOI: 10.1200/Jco.2018.36.15_Suppl.9579  0
2018 Krieg C, Nowicka M, Guglietta S, Schindler S, Hartmann FJ, Weber LM, Dummer R, Robinson MD, Levesque MP, Becher B. Abstract 566: High dimensional single cell analysis predicts response to anti-PD-1 immunotherapy Cancer Research. 78: 566-566. DOI: 10.1158/1538-7445.Am2018-566  0
2017 Jacquelot N, Roberti MP, Enot DP, Rusakiewicz S, Ternès N, Jegou S, Woods DM, Sodré AL, Hansen M, Meirow Y, Sade-Feldman M, Burra A, Kwek SS, Flament C, Messaoudene M, ... ... Levesque M, et al. Predictors of responses to immune checkpoint blockade in advanced melanoma. Nature Communications. 8: 592. PMID 28928380 DOI: 10.1038/S41467-017-00608-2  0
2017 Behera R, Kaur A, Webster MR, Kim S, Ndoye A, Kugel CH, Alicea GM, Wang JX, Ghosh K, Cheng PF, Lisanti S, Marchbank K, Dang V, Levesque MP, Dummer R, et al. Inhibition of age-related therapy resistance in melanoma by rosiglitazone-mediated induction of Klotho. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 28232477 DOI: 10.1158/1078-0432.Ccr-17-0201  0
2017 Dhar S, Chiovaro F, Tanos T, Hejhal T, Heilemariam S, Kelm J, Irmisch A, Levesque M. Abstract 5781: Establishment of a 3Dex-vivoassay as a preclinical drug testing platform for personalized cancer therapy Cancer Research. 77: 5781-5781. DOI: 10.1158/1538-7445.Am2017-5781  0
2016 Goldinger SM, Courtier A, Jaberg-Bentele NF, Schindler S, Manuel M, Plantier N, Treillard B, Noel M, Nguyen-Kim TDL, Raaijmakers MIG, Kvistborg P, Haanen JBAG, Dummer R, Levesque M. The peripheral blood TCR repertoire to facilitate patient stratification for immune checkpoint blockade inhibition in metastatic melanoma. Journal of Clinical Oncology. 34: 3026-3026. DOI: 10.1200/Jco.2016.34.15_Suppl.3026  0
2016 Flueckiger S, Aloia A, Frischknecht L, Tuozzo A, Croci D, Shakhova O, Britschgi C, Dummer R, Levesque MP, Krek W. Abstract 300: Inhibition of oncogenic MAPK signaling in melanoma triggers SOX2-dependent adaptive drug resistance Cancer Research. 76: 300-300. DOI: 10.1158/1538-7445.Am2016-300  0
2016 Flueckiger S, Aloia A, Frischknecht L, Tuozzo A, Croci D, Shakhova O, Britschgi C, Levesque MP, Dummer R, Krek W. Inhibition of oncogenic MAPK signaling in melanoma triggers SOX2-dependent adaptive drug resistance programs European Journal of Cancer. 61. DOI: 10.1016/S0959-8049(16)61726-4  0
2015 Otsuka A, Dreier J, Cheng P, Nägeli M, Levesque MP, Dummer R. 3349 Hedgehog pathway inhibitors promote adaptive immune responses in basal cell carcinoma European Journal of Cancer. 51. DOI: 10.1016/S0959-8049(16)31867-6  0
2013 McMahon M, Thakur MD, Marsh V, Silva J, Landman A, Deuker M, Salangsang F, Pryer N, Phillips W, Levesque M, Dummer R, Bosenberg M, Sellers WR, Stuart D. Abstract SY17-03: Targeting BRAF and PI3′-kinase signaling for therapy of melanoma. Cancer Research. 73. DOI: 10.1158/1538-7445.Am2013-Sy17-03  0
2013 Thakur MD, Fisher R, Salangsang F, Landman A, Sellers W, Pryer N, Levesque MP, Dummer R, Gore M, Larkin J, McMahon M, Stuart D. Abstract LB-144: Modeling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance. Cancer Research. 73. DOI: 10.1158/1538-7445.Am2013-Lb-144  0
2006 Levesque MP, Vernoux T, Busch W, Cui H, Wang JY, Blilou I, Hassan H, Nakajima K, Matsumoto N, Lohmann JU, Scheres B, Benfey PN. Correction: Whole-Genome Analysis of the SHORT-ROOT Developmental Pathway in Arabidopsis Plos Biology. 4: e249. DOI: 10.1371/Journal.Pbio.0040249  0
Hide low-probability matches.